| Authors: |
Kamphuis JBJ; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France., Worrall WPM; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France., Stackowicz J; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, 75015 Paris, France.; Sorbonne Université, 75006 Paris, France., Mougel A; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France., Mauré E; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France., Conde E; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, 75015 Paris, France.; Sorbonne Université, 75006 Paris, France., Bruhns P; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, 75015 Paris, France., Guilleminault L; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France.; Department of Respiratory Medicine, Toulouse University Hospital, Faculty of Medicine, 31059 Toulouse, France., Gaudenzio N; Unité de Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056, INSERM, Université de Toulouse, 31059 Toulouse, France., Chen J; Singapore Immunology Network, Agency for Science, Technology and Research, 138648 Singapore., Gentek R; Centre for Inflammation Research, University of Edinburgh, EH16 4TJ Edinburgh, UK., Reber LL; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France. laurent.reber@inserm.fr.; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, 75015 Paris, France. |
